Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
HTN.
|
|
Dosage/Direction for Use
Adult: PO 150 mg once daily, increased to 300 mg once daily if needed.
|
|
Administration
May be taken with or without food. Take consistently w/ or w/o meals. Avoid taking w/ high fat meals.
|
|
Contraindications
History of angioedema; severe renal impairment. Concomitant use w/ ACE inhibitors or angiotensin II receptor antagonists in patients w/ DM and renal impairment (GFR <60 mL/min). Concomitant use w/ ciclosporin, itraconazole and quinidine. Pregnancy.
|
|
Special Precautions
Serious CHF, sodium or volume depletion. Discontinue if diarrhoea is severe and persistent. Lactation. Monitoring Parameters Periodically monitor serum potassium concentration and renal function.
|
|
Adverse Reactions
Diarrhoea, dyspepsia, GERD, abdominal pain, hypotension, headache, fatigue, dizziness, back pain, cough, rashes, hyperuricaemia, gout, renal calculi, hyperkalaemia, decreases in Hb levels (dose-related), angioedema and seizures.
Potentially Fatal: Anaphylactic reactions. |
|
Drug Interactions
Increased risk of hypotension w/ other antihypertensives. Increased risk of acute renal failure w/ ACE inhibitors, angiotensin II receptor antagonists or NSAIDs. Antihypertensive effect may be reduced w/ NSAIDs. Increased serum levels w/ atorvastatin, itraconazole, ketoconazole, verapamil. Significant decrease in furosemide concentrations w/ aliskiren. Increased risk of hyperkalaemia w/ potassium-sparing diuretics, potassium supplements or any substances that may increase serum potassium levels.
|
|
CIMS Class
|
|
ATC Classification
C09XA02 - aliskiren ; Belongs to the class of renin-inhibitors. Used in the treatment of cardiovascular disease.
|
